Cargando…
PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer
OBJECTIVE: Neuroendocrine cervical cancer (NECC) is a rare cervical cancer with high aggressivity that causes poor prognosis even in the early stage. Given other neuroendocrine carcinomas and other types of cervical cancer have been proved to have expression of programmed cell death protein 1 ligand...
Autores principales: | Ji, Xiaoyu, Sui, Lei, Song, Kejuan, Lv, Teng, Zhao, Han, Yao, Qin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290238/ https://www.ncbi.nlm.nih.gov/pubmed/34076351 http://dx.doi.org/10.1002/cam4.4034 |
Ejemplares similares
-
Two novel and one known pathogenic germline mutations in MMRs in Chinese families with Lynch syndrome
por: Li, Juyi, et al.
Publicado: (2021) -
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
por: Kim, Chiho, et al.
Publicado: (2020) -
Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor
por: Inamura, Kentaro, et al.
Publicado: (2017) -
Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021) -
Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)